Authors
Benjamin Brennecke, Louise Plais, Benoit Hornsperger, Martin Binder, Christian Bartelmus, Markus Bürkler, Fionn O'Hara, Carsten Kroll, Satoshi Tsuchiya, Buelent Kocer, Hans Richter, Martin Ritter, Katrin Groebke Zbinden, Maude Giroud, Manfred Schneider, Andrea Martella, Ann Petersen, Wiebke Saal, Melanie Guerard, Axel Pähler, Luca Gobbi, Antonia F Stepan, Moreno Wichert, Andreas Topp, Dominik Heer, Iris Ruf, Remo Hochstrasser, Manuel Hilbert, Sylwia Huber, Anto Pavlovic, Juliane Stephanus, Sina Simon, Achi Haider, Mario van der Stelt, Matthias Beat Wittwer, Ludovic Collin, Jörg Benz, Bernd Kuhn, Uwe Grether
Published in
Journal of medicinal chemistry. Volume 69. Issue 21. Pages 25832-25854. Nov 12, 2026.
Abstract
Monoacylglycerol lipase (MAGL) is a promising therapeutic target for neuroinflammatory conditions. We have previously reported on MAGLi 432, a reversible MAGL inhibitor with activity in mouse models of neuroinflammation. In this full account, we report on the structure-guided optimization of a bicyclopiperazine (Bcpz) DEL hit into potent, selective and brain-penetrant reversible MAGL inhibitor 1.5 (MAGLi 432), guided by the "Five-Star Matrix" translational framework. Compound 1.5 combines excellent MAGL potency (IC50 = 3.2 nM) and selectivity over other serine hydrolases with favorable pharmacokinetic properties, including a 5.7 h half-life after oral administration in male Wistar rats, and CNS drug-like potential. Furthermore, as previously reported, the compound demonstrated robust brain penetration and efficacy in preclinical mouse models of neuroinflammation correlating with inhibition of MAGL activity in mouse and human brain homogenate. This work highlights the power of combining DEL screening and SBDD with the Five-Star Matrix to deliver drug-like candidates for neuroinflammatory disorders.
PMID:
43018548
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 12
- Comments 0